



Financial Tear Sheet

Corporate Profile

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and progressing its pipeline of novel therapeutic candidates in cancer, cachexia (wasting syndrome) and Pulmonary Arterial Hypertension (PAH).

AVEO Oncology
Investor Relations
Phone: 617-588-1960
E-mail:
ir@aveooncology.com

Stock Performance

AVEO (COMMON STOCK)

Exchange	NASDAQ (US Dollar)
Price	\$2.53
Change (%)	▲ 0.08 (3.27%)
Volume	3,104,133
52 Week Low	\$0.50
Market Cap	\$279,218,253
Rolling EPS	-0.38
PE Ratio	N/A

Shares Outstanding 110,362,946

Data as of 07/27/17 4:00 p.m. ET



Recent Headlines

06/27/17

AVEO Oncology Announces \$14M in Aggregate Gross Proceeds from Hercules Credit Facility and At-the-market Stock Offerings

06/23/17

AVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell Carcinoma

06/20/17

AVEO Oncology Announces Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma Reaches Enrollment Target

Events

There are currently no events scheduled.

SEC Filings

FILING DATE FORM

07/05/17	4
06/28/17	4
06/28/17	4
06/27/17	8-K

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed